{"id":"hs-20089","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperphosphatemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL4297389","moleculeType":"Small molecule","molecularWeight":"421.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HS-20089 targets FGFR kinase activity to inhibit downstream proliferation and survival pathways in tumors with FGFR alterations. By selectively blocking FGFR signaling, the drug aims to suppress tumor growth in cancers driven by FGFR mutations, fusions, or amplifications.","oneSentence":"HS-20089 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:45:59.749Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"FGFR-altered solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT06855069","phase":"PHASE3","title":"HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer","status":"RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2025-03-13","conditions":"Ovarian Cancer","enrollment":468},{"nctId":"NCT06769425","phase":"PHASE1","title":"HS-10502 Combination Treatment in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2025-05-07","conditions":"Recurrent Ovarian Cancer, HER2-negative, Advanced Breast Cancer","enrollment":157},{"nctId":"NCT06014190","phase":"PHASE2","title":"HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer","status":"RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2023-12-18","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":460},{"nctId":"NCT06336707","phase":"PHASE1","title":"HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2024-04-11","conditions":"Advanced Solid Tumors","enrollment":1048},{"nctId":"NCT05263479","phase":"PHASE1","title":"A Study of HS-20089 in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Shanghai Hansoh Biomedical Co., Ltd","startDate":"2022-01-05","conditions":"Advanced Solid Tumor","enrollment":177}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HS-20089","genericName":"HS-20089","companyName":"Hansoh BioMedical R&D Company","companyId":"hansoh-biomedical-r-d-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HS-20089 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. Used for FGFR-altered solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}